Recombinant Human Erythropoietin in Combination with Chemotherapy Increases Breast Cancer Metastasis in Preclinical Mouse Models

摘要: Purpose: Erythropoiesis-stimulating agents (ESAs) are used clinically for treating cancer-related anemia. Recent clinical trials have reported increased adverse events and reduced survival in ESA-treated breast cancer patients receiving chemotherapy, potentially related to erythropoietin (EPO)-induced progression. However, minimal pre-clinical data is available regarding the impact of EPO on metastatic cell behavior and/or process, this was goal our study. Experimental Design: Breast lines were treated with recombinant human (rHuEPO) screened expression EPOR. MDA-MB-231 MDA-MB-435 functional assays vitro (2D/3D growth, survival) vivo (tumorigenicity, metastasis), presence or absence cytotoxic agents. Results: A large variation EPOR across observed. In vitro, rHuEPO had a protective effect radiation-treated cells (p<0.05), however treatment alone combined chemotherapy hypoxia did not influence survival. vivo, lung metastases immunocompromised mice injected relative (p<0.05). Conclusions: The lack an rhEPO highlights importance studies delineate effects process. These may begin uncover underlying explanation observed EPO-related decreased undergoing chemotherapy.